Please assess the completion status of the following clinical trial:

Trial Title: Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Cryopreserved buffy coat pooled platelets will be infused, after being thawed, in inpatients at U.O. of Hematology -Policlinic P. Giaccone-Palermo, falling into one of the following categories:~* Stable clinical conditions and no complications with platelets ≤ 10,000/microliter;~* With active bleeding and ≤ 20,000 platelets/microliter;~* In the presence of: high blood pressure, high fever, rapid drop in platelets, infection, chemotherapy, coagulation abnormalities with ≤ 20,000 platelets/microliter.~Exclusion Criteria:~Patients~* Suffering from congenital immunodeficiency~* Allogeneic bone marrow transplant candidates~* Bone Marrow Donors for transplantation~* Undergoing bone marrow transplant or~* Suffering from Hodgkin's disease and treated with purine analogues (Fludarabine, cladribine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with severe thrombocytopenia (Type: OTHER): Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System

Based on this trial design, predict the completion outcome and termination type (if applicable).